THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE
申请人:Rossello Armando
公开号:US20090239829A1
公开(公告)日:2009-09-24
There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R
1
, R
2
, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.
[EN] 6-MEMBERED URACIL ISOSTERES<br/>[FR] ISOSTÈRES D'URACILE À 6 CHAÎNONS
申请人:CV6 THERAPEUTICS NI LTD
公开号:WO2018098204A1
公开(公告)日:2018-05-31
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
本文件提供了dUTPase抑制剂,包含此类化合物的组合物以及使用此类化合物和组合物的方法。
Process for preparing diacid compounds
申请人:RHODIA OPERATIONS
公开号:US20150175515A1
公开(公告)日:2015-06-25
The present invention relates to a process for preparing at least one diacid compound, comprising a step of hydrolysis reaction of at least one imide compound, performed in the absence of catalyst.
[EN] BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY<br/>[FR] MOLÉCULES BIFONCTIONNELLES CONTENANT UNE FRACTION DE LIAISON À L'UBIQUITINE LIGASE E3 LIÉE À UNE FRACTION CIBLANT BCL6
申请人:ARVINAS OPERATIONS INC
公开号:WO2021077010A1
公开(公告)日:2021-04-22
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.